Literatur
- 1
Schiefke I, Zabel-Langhennig A, Neumann S, Feisthammel J, Moessner J, Caca K.
Long term failure of endoscopic gastroplication (EndoCinch).
Gut.
2005;
54
752-758
- 2
Barr H, Stone N, Rembacken B.
Recent advances in clinical practice: Endoscopic therapy of Barett’s oesophagus.
Gut.
2005;
54
875-884
- 3
Dulai G S, Shekelle P G, Jensen D M, Spiegel B MR, Chen J, Oh D, Kahn K L.
Dysplasia and risk of further neoplastic progression in a regional veterans administration
Barrett’s cohort.
Am J Gastroenterol.
2005;
100
775-783
- 4
Spechler S J.
Dysplasia in Barrett’s esophagus: limitations of current management strategies.
Am J Gastroenterol.
2005;
100
927-935
- 5
Crowe S E.
Helicobacter infection, chronic inflammation, and the development of malignancy.
Curr Opin Gastroenterol.
2005;
21
32-38
- 6
Nardone G, Rocco A, Malfertheiner P.
Helicobacter pylori and molecular events in precancerous gastric lesions.
Aliment Pharmacol Ther.
2004;
20
261-270
- 7
Chan A O, Lam S K, Wong B C. et al .
Promoter methylation of E-cadherin gene in gastric musoca associated with Helicobacter
pylori infection and in gastric cancer.
Gut.
2003;
52
261-270
- 8
Carneiro F, Huntsman D G, Smyrk T C. et al .
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers
and its implications for patient screening.
J Pathol.
2004;
203
681-687
- 9
Higashi H, Nakaya A, Tsutsumi R. et al .
Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2
recruitment and activation.
J Biol Chem.
2004;
279
17 205-17 216
- 10
Rad R, Dossumbekova A, Neu B. et al .
Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation,
and host specific colonisation during Helicobacter pylori infection.
Gut.
2004;
53
1082-1089
- 11
Graham D Y, Shiotani A.
The time to eradicate gastric cancer is now.
Gut.
2005;
54
735-738
- 12
Nagar A B, Gorelick F S.
Acute pancreatitis.
Curr Opin Gastroenterol.
2004;
20
439-443
- 13
DiMagno M J, DiMagno E P.
Chronic pancreatitis.
Curr Opin Gastroenterol.
2004;
20
444-451
- 14
Kim K P, Kim M H, Song M H, Lee S S, Seo D W, Lee S K.
Autoimmune chronic pancreatitis.
Am J Gastroenterol.
2004;
99
1605-1616
- 15
Arvanitakis M, Delhaye M, De Maertelaere V. et al .
Computer tomography and magnetic resonance imaging in the assessment of acute pancreatitis.
Gastroenterology.
2004;
126
715-723
- 16
Pietrangelo A.
Hereditary hemochromatosis - a new look at an old disease.
N Engl J Med.
2004;
350
2383-2397
- 17
Sass D A, Chang P, Chopra K B.
Nonalcoholic fatty liver disease: a clinical review.
Dig Dis Sci.
2005;
50
171-180
- 18
Ratziu V, Poynard T.
NASH: a hidden and silent fibroser finally revealed?.
J Hepatol.
2005;
42
12-14
- 19
Adams L A, Schuyler S, Lindor K D, Angulo P.
The histological course of nonalcoholic fatty liver disease: a longitudinal study
of 103 patients with sequential liver biopsies.
J Hepatol.
2005;
42
132-138
- 20
Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler C F, Patsch J R,
Tilg H.
Adiponectin and its receptors in non-alcoholic steatohepatitis.
Gut.
2005;
54
117-121
- 21
Javor E D, Ghany M G, Cochran E K, Oral E A, DePaoli A M, Premkumar A, Kleiner D E,
Gorden P.
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Hepatology.
2005;
41
753-760
- 22
Adams L A, Zein C, Angulo P, Lindor K D.
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
Am J Gastroenterol.
2004;
99
2365-2368
- 23
Uygun A, Kadayifci A, Isik A T, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M,
Dagalp K.
Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Aliment Pharmacol Ther.
2004;
19
537-544
- 24
Nair S, Diehl A M, Wiseman M, Farr G H, Perrillo R P.
Metformin in the tretment of non-alcoholic steatohepatitis: a pilot label trial.
Aliment Pharmacol Ther.
2004;
20
23-28
- 25
Tilg H, Kaser A.
Treatment strategies in nonalcoholic fatty liver disease.
Nat Clin Pract Gastr.
2005;
2
148-155
- 26
Charlton M.
Nonalcoholic Fatty liver disease: a review of current understanding and future impact.
Clin Gastroenterol Hepatol.
2004;
2
1048-1058
- 27
Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, Hellerbrand C,
Kuth J, Schanz S, Kahl S, Fleig W E, Sauerbruch T.
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.
Hepatology.
2004;
40
65-72
- 28
Sarin S K, Wadhawan M, Agarwal S R, Tyagi P, Sharma B C.
Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation
alone in primary prophylaxis of variceal bleeding.
Am J Gastroenterol.
2005;
100
797-804
- 29
Garcia-Tsao G.
Portal hypertension.
Curr Opin Gastroenterol.
2005;
21
313-322
- 30
Llovet J M.
Updated treatment approach to hepatocellular carcinoma.
J Gastroenterol.
2005;
40
225-235
- 31
Bruix J, Sala M, Llovet J M.
Chemoembolization for hepatocellular carcinoma.
Gastroenterology.
2004;
127
S179-S188
- 32
Bernatik T, Becker D, Neureiter D, Hansler J H, Frieser M, Schaber S, Wein A, Hahn E G,
Strobel D.
Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the
liver.
Eur J Gastroenterol Hepatol.
2004;
16
313-317
- 33
Schlottmann K, Kratzer W, Schölmerich J.
Doppler ultrasound and intravenous contrast agents in gastrointestinal tract disorders:
current role and future implications.
Eur J Gastroenterol Hepatol.
2005;
17
263-275
- 34
Tsai C J, Leitzmann M F, Willet W C, Giovannucci E L.
Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone
disease in men.
Gut.
2005;
54
823-828
- 35
Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M.
Genetics of Crohn disease, an archetypal inflammatory barrier.
Nat Rev Genet.
2005;
6
376-388
- 36
Török H P, Glas J, Tonenchi L, Lohse P, Müller-Myhsok B, Limbersky O, Neugebauer C,
Schnitzler F, Seiderer J, Tillack C, Brand S, Brünnler S, Jagiello P, Epplen J T,
Griga T, Klein W, Schiemann U, Folwaczny M, Ochsenkühn T, Folwaczny C.
Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn’s disease.
Gut.
2005;
im Druck
- 37
Noble C L, Nimmo E R, Drummond H, Smith L, Arnott I D, Satsangi J.
DLG5 variants do not influence susceptibility to inflammatory bowel disease in the
Scottish population.
Gut.
2005;
im Druck
- 38
Watanabe T, Kitani A, Murray P J, Strober W.
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.
Nat Immunol.
2004;
5
776-778
- 39
Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger K R,
Stallmach A, Noack F, Fritz P, Schroder J M, Bevins C L, Fellermann K, Stange E F.
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal
alpha-defensin expression.
Gut.
2004;
53
1558-1560
- 40
Kobayashi K S, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell R A.
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.
Science.
2005;
307
731-734
- 41
Maeda S, Hsu L C, Liu H, Bankston L A, Iimura M, Kagnoff M F, Eckmann L, Karin M.
Nod2 mutation in Crohn’s disease potentiates NF-κB activity and IL-1β processing.
Science.
2005;
307
734
- 42
Eckmann L.
Defence molecules in intestinal innate immunity against bacterial infections.
Curr Opin Gastroenterol.
2005;
21
147-151
- 43
Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U,
Nuding S, Bengmark S, Fellermann K, Schroder J M, Stange E F.
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial
cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.
Infect Immun.
2004;
72
5750-5758
- 44 Schölmerich J. Biological therapies. In: Bernstein, C. (Ed.): IBD-yearbook 2005:
im Druck
- 45
Ljung T, Karlen P, Schmidt D, Hellstrom P M, Lapidus A, Janczewska I, Sjoqvist U,
Lofberg R.
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort
from Stockholm County.
Gut.
2004;
53
849-853
- 46
Colombel J F, Loftus E V, Tremaine W J, Egan L J, Harmsen W S, Schleck C D, Zinsmeister A R,
Sandborn W J.
The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic
experience in 500 patients.
Gastroenterology.
2004;
126
19-31
- 47
Van den Brande J, Hommes D W, Peppelenbosch M P.
Infliximab induced T lymphocyte apoptosis in Crohn’s disease.
J Rheumatol Suppl.
2005;
74
26-30
- 48
Schreyer A G, Geissler A, Albrich H, Schölmerich J, Feuerbach S, Rogler G, Völk M,
Herfarth H.
Abdominal MRI after enteroclysis or with oral contrast in patients with suspected
or proven Crohn’s disease.
Clin Gastroenterol Hepatol.
2004;
2
491-497
- 49
Schreyer A G, Gölder S, Scheibl K, Völk M, Lenhart M, Timmer A, Schölmerich J, Feuerbach S,
Rogler G, Herfarth H, Seitz J.
Dark lumen magnetic resonance enteroclysis in combination with MRI colonography for
whole bowel assessment in patients with Crohn’s disease: first clinical experience.
Inflamm Bowel Dis.
2005;
11
388-394
- 50
Schreyer A G, Rath H C, Kikinis R, Völk M, Schölmerich J, Feuerbach S, Rogler G, Seitz J,
Herfarth H.
Comparison of magnetic resonance imaging colonography with conventional colonoscopy
for the assessment of intestinal inflammation in patients with inflammatory bowel
disease: a feasibility study.
Gut.
2005;
54
250-256
- 51
Gölder S K, Schreyer A G, Endlicher E, Feuerbach S, Schölmerich J, Kullmann F, Seitz J,
Rogler G, Herfarth H.
Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected
small bowel disease.
Int J Colorectal Dis.
2005;
im Druck
- 52
Hartmann D, Schmidt H, Bolz G, Schilling D, Kinzel F, Eickhoff A, Huschner W, Möller K,
Jakobs R, Reitzig P, Weickert U, Gellert K, Schultz H, Guenther K, Hollerbuhl H, Schoenleben K,
Schulz H -J, Riemann J F.
A prospective two-center study comparing wireless capsule endoscopy with intraoperative
enteroscopy in patients with obscure gastrointestinal bleeding.
Gastrointest Endosc.
2005;
im Druck
- 53
Keroack M.
Video capsule endoscopy.
Curr Opin Gastroenterol.
2004;
20
474-481
- 54
Gionchetti P, Morselli C, Rizzello F, Romagnoli R, Campieri M, Poggioli G, Laureti S,
Ugolini F, Pierangeli F.
Management of pouch dysfunction or pouchitis with an ileoanal pouch.
Best Pract Res Clin Gastroenterol.
2004;
18
993-1006
- 55
Kruis W, Fric P, Pokrotnicks J, Lukas M, Fixa B, Kascak M, Kamm M A, Weismueller J,
Beglinger C, Stolte M, Wolff C, Schulze J.
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle
1917 is as effective as with standard mesalazine.
Gut.
2004;
53
1617-1623
- 56
Hart A L, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm M A,
Knight S C, Stagg A J.
Modulation of human dendritic cell phenotype and function by probiotic bacteria.
Gut.
2004;
53
1602-1609
- 57
Summers R W, Elliott D E, Urban J F, Thompson R A, Weinstock J V.
Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.
Gastroenterology.
2005;
128
1117-1119
- 58
Summers R W, Elliott D E, Urban J F, Thompson R A, Weinstock J V.
Trichuris suis therapy in Crohn’s disease.
Gut.
2005;
54
87-90
- 59
Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall J W, Kim H M,
Weiss D G, Emory T, Schatzkin A, Lieberman D.
Colonoscopic screening of average-risk women for colorectal neoplasia.
N Engl J Med.
2005;
352
2061-2068
- 60
Agrawal J, Syngal S.
Colon cancer screening strategies.
Curr Opin Gastroenterol.
2005;
21
59-63
- 61
Fletcher J G, Booya F, Johnson C D, Ahlquist D.
CT colonography: unraveling the twists and turns.
Curr Opin Gastroenterol.
2005;
21
90-98
- 62
Riemann J F.
Gastroenterologie: Neue Denkgebäude, faszinierende Wege und Schnittstelle zur Chirurgie.
Dtsch Med Wochenschr.
1999;
124
1546-1549
Prof. Dr. Jürgen Schölmerich
Klinik und Poliklinik für Innere Medizin I der Universität Regensburg
Klinikum
93042 Regensburg
Telefon: 0941/9447000
Fax: 0941/9447002
eMail: juergen.schoelmerich@klinik.uni-r.de
